Q32 Bio Inc.

Revolutionizing the future of targeted immune therapeutics

Add To Watchlist
General Information
Company Name
Q32 Bio Inc.
Founded Year
2017
Location (Offices)
Waltham, United States +1
Founders / Decision Makers
Maria Marzilli - Head of Corporate Development Jason A Campagna Campagna - Chief Medical Officer Lee Kalowski - President and CFO Adam Cutler - Chief Financial Officer
Number of Employees
46
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Post Ipo Equity
Social Media

Q32 Bio Inc. - Company Profile

Q32 Bio Inc. is a leading biotechnology company with a mission to revolutionize the future of targeted immune therapeutics. Established in 2017, the company is headquartered in the United States. Q32 Bio is dedicated to developing innovative therapeutics that target powerful regulators of the innate and adaptive immune systems, with a focus on the IL-7 pathway and complement system. This targeted approach aims to re-balance the immune system in severe autoimmune and inflammatory diseases, providing new hope for patients facing conditions with limited treatment options. The company's commitment to addressing immune system dysregulation has garnered significant attention, as evidenced by its recent $42.00M Venture Round investment on 25 March 2024. Notable investors in this round include Atlas Venture, Abingworth, OrbiMed, Osage University Partners, Acorn Bioventures, Agent Capital, CU Healthcare Innovation Fund, Sanofi Ventures, Homology Medicines, and Bristol-Myers Squibb.

Taxonomy: immune therapeutics, IL-7 pathway, complement system, autoimmune diseases, inflammatory diseases, immunotherapy, immune system regulation, treatment options, therapeutics development, dysregulation, innovative biotech, immune modulation, precision medicine, startup biotech

Funding Rounds & Investors of Q32 Bio Inc. (3)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $42.00M 10
Atlas Venture, investor in Q32 Bio Inc.'s Post-IPO Equity round Abingworth, investor in Q32 Bio Inc.'s Post-IPO Equity round OrbiMed, investor in Q32 Bio Inc.'s Post-IPO Equity round Acorn Bioventures, investor in Q32 Bio Inc.'s Post-IPO Equity round Agent Capital, investor in Q32 Bio Inc.'s Post-IPO Equity round Sanofi Ventures, investor in Q32 Bio Inc.'s Post-IPO Equity round
Homology Medicines, Bristol-Myers Squibb +2 		25 Mar 2024
Series B $60.00M - 29 Oct 2020
Series A $46.00M - 27 May 2020

Latest News of Q32 Bio Inc.

View All

No recent news or press coverage available for Q32 Bio Inc..

Similar Companies to Q32 Bio Inc.

View All
Cogen Therapeutics - Similar company to Q32 Bio Inc.
Cogen Therapeutics Pioneering immune modulation to specifically address disease drivers, redefining immunological health with advanced understandings of immune cell biology.
Asylia Therapeutics - Similar company to Q32 Bio Inc.
Asylia Therapeutics Innovative therapies reshaping immune responses against autoimmune, cancer, and infectious diseases.
Georgiamune Inc. - Similar company to Q32 Bio Inc.
Georgiamune Inc. Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fight diseases.
Nuvig Therapeutics Inc. - Similar company to Q32 Bio Inc.
Nuvig Therapeutics Inc. Rebalancing Immune Function for Chronic Inflammatory and Autoimmune Diseases
Cerberus Therapeutics - Similar company to Q32 Bio Inc.
Cerberus Therapeutics Modulating immunity with the small—yet, mighty—nanobody
Circle Decoration Circle Decoration

Want to dive deeper into Q32 Bio Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now